CIK: 0001844645
Total reported value
$279.8M
Reporting period: 2026-03-31 · Number of holdings: 13
Pivotal bioVenture Partners Investment Advisor LLC disclosed 13 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $279.8M and a quarterly turnover rate of 23.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "P"
Pivotal bioVenture Partners Investment Advisor LLC's disclosed holdings carry a Herfindahl concentration index of 0.158 — mathematically equivalent to about 6 equally-sized positions, well below its 13 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 1.07), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 4.8 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 1% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim ZBIO
0.0% -$9.9M
Add PCVX
0.0% $16.4M
Trim ARQT
-0.8% -$7.7M
Add EVMN
0.0% $11.3M
Trim OCS
-26.6% -$1.0M
Add BIOA
0.0% $2.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte INC | Stock-Other | 28.51% | +4.03% | — | |
| 2 | OCS | Oculis Holding AG | Stock-Other | 15.97% | -1.70% | -26.58% | |
| 3 | EVMN | Evommune INC | Stock-Other | 15.83% | +3.08% | — | |
| 4 | ARQT | Arcutis Biotherapeutics INC | Stock-Other | 11.42% | -3.92% | -0.79% | |
| 5 | TRVI | Trevi Therapeutics INC | Stock-Other | 6.63% | +0.55% | +23.63% | |
| 6 | IMNM | Immunome INC | Stock-Other | 5.73% | -0.35% | — | |
| 7 | MPLT | Maplight Therapeutics INC | Stock-Other | 4.44% | +0.29% | — | |
| 8 | ZBIO | Zenas Biopharma INC | Stock-Other | 4.14% | -4.17% | — | |
| 9 | BIOA | Bioage Labs INC | Stock-Other | 4.08% | +0.74% | — | |
| 10 | AVTX | Avalo Therapeutics INC | Stock-Other | 1.58% | +1.58% | NEW | |
| 11 | RLYB | Rallybio CORP | Stock-Other | 0.96% | +0.96% | NEW | |
| 12 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.65% | -0.29% | — | |
| 13 | BOLT | Bolt Biotherapeutics INC | Stock-Other | 0.06% | -0.14% | -54.98% |
Performance for Q3 2026
-1.2%
Performance Last 4 Quarters
+75.3%
Based on 72% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 13 | $279.8M | 24 | |
| 2025-12-31 | 12 | $258.7M | 40 | |
| 2025-09-30 | 10 | $173.0M | 42 | |
| 2025-06-30 | 12 | $161.3M | 0 | |
| 2025-03-31 | 11 | $123.6M | 100 | |
| 2024-12-31 | 11 | $148.1M | 0 | |
| 2024-09-30 | 11 | $168.5M | 0 | |
| 2024-06-30 | 10 | $130.1M | 0 | |
| 2024-03-31 | 11 | $155.6M | 0 | |
| 2023-12-31 | 13 | $394.2M | 0 | |
| 2023-09-30 | 13 | $250.7M | 0 | |
| 2023-06-30 | 11 | $303.3M | 0 | |
| 2023-03-31 | 11 | $242.9M | 0 | |
| 2022-12-31 | 10 | $230.0M | 0 | |
| 2022-09-30 | 11 | $273.7M | 0 | |
| 2022-06-30 | 11 | $198.5M | 0 | |
| 2022-03-31 | 11 | $211.4M | 0 | |
| 2021-12-31 | 10 | $239.2M | 0 | |
| 2021-09-30 | 9 | $282.9M | 0 | |
| 2021-06-30 | 8 | $253.7M | 23 | |
| 2021-03-31 | 9 | $311.7M | 38 | |
| 2020-12-31 | 9 | $303.3M | — |
Pivotal bioVenture Partners Investment Advisor LLC's most significant position changes for 2026-03-31: New buy: Avalo Therapeutics INC (AVTX); New buy: Rallybio CORP (RLYB); Sold out: Rallybio CORP; Trim: Arcutis Biotherapeutics INC (ARQT) — shares -0.79%; Trim: Oculis Holding AG (OCS) — shares -26.58%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte INC | +4% | — | Unchanged |
| 2 | EVMN | Evommune INC | +3.1% | — | Unchanged |
| 3 | BIOA | Bioage Labs INC | +0.7% | — | Unchanged |
| 4 | TRVI | Trevi Therapeutics INC | +0.6% | +23.63% | Add |
| 5 | MPLT | Maplight Therapeutics INC | +0.3% | — | Unchanged |
| 6 | BOLT | Bolt Biotherapeutics INC | -0.1% | -54.98% | Trim |
| 7 | RXRX | Recursion Pharmaceuticals-a | -0.3% | — | Unchanged |
| 8 | IMNM | Immunome INC | -0.4% | — | Unchanged |
| 9 | OCS | Oculis Holding AG | -1.7% | -26.58% | Trim |
| 10 | ARQT | Arcutis Biotherapeutics INC | -3.9% | -0.79% | Trim |
| 11 | ZBIO | Zenas Biopharma INC | -4.2% | — | Unchanged |
| 12 | AVTX | Avalo Therapeutics INC | — | NEW | New buy |
| 13 | RLYB | Rallybio CORP | — | NEW | New buy |
| 14 | ✓ | Rallybio CORP | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-13 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-13 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-13 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-14 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-13 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-14 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-13 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-13 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-11 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-12 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-13 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-10 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-12 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-14 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-09 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001122490
Total reported value
$279.8M
107 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001775391
Total reported value
$279.7M
169 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001811005
Total reported value
$279.9M
201 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001782539
Total reported value
$121.3M
24 stks
2026-03-31
2 of the top 5 holdings overlap, including Evommune INC
CIK 0001834239
Total reported value
$1.0B
5 stks
2026-03-31
2 of the top 5 holdings overlap, including Oculis Holding AG
CIK 0001274413
Total reported value
$120.7M
77 stks
2026-03-31
1 of the top 5 holdings overlap, including Evommune INC